TVGN TEVOGEN BIO HOLDINGS INC

Dr. Ryan Saadi Commends Individuals Who Dedicate Time to Public Service, and Congratulates Mayor Victor Sordillo on His Induction Into the NJ League of Municipalities Hall of Fame

Dr. Ryan Saadi Commends Individuals Who Dedicate Time to Public Service, and Congratulates Mayor Victor Sordillo on His Induction Into the NJ League of Municipalities Hall of Fame



WARREN, N.J., Dec. 05, 2024 (GLOBE NEWSWIRE) -- , CEO of (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: ), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, congratulates Board Member, PE, CSP, MBA, as he was inducted into The New Jersey League of Municipalities Hall of Fame this month.

Mayor Sordillo was inducted into the Hall of Fame for his dedicated tenure of 24 years of continuous service as a Warren Township Committee Member. As an elected official, Mayor Sordillo served the community by leading the municipal government, providing oversight to the township’s operations, and implementing policies for the public good, essentially working for the benefit of the citizens he represents.

“Mayor Sordillo exemplifies the qualities of a dedicated public servant, making personal sacrifices to answer a call that many shy away from. While policy debates are essential and differing perspectives form the bedrock of democracy, such discussions are incomplete without acknowledging the personal commitments and sacrifices made by leaders like Mayor Sordillo. We extend our deepest gratitude and congratulations on your remarkable service.” said Ryan Saadi, MD, MPH, Tevogen Bio’s Chief Executive Officer.

“It has been an honor to serve the residents of Warren and be part of a very high performing team of committee people. During our tenure, we built a new library, a new town hall, extensive youth facilities including the football complex, playgrounds, and basketball courts; and purchased around 1,000 acres of open space which includes the Wagner Farm. This was accomplished while maintaining a AAA bond rating and having one tenth of the long-term debt allowable by the State of NJ.” said Mayor Sordillo.

Former New Jersey Governor Don DeFrancesco and current State Senator John Bramnick recognized Warren Township and its leadership, both having said that the Township is a model for the State and one of the best places to live. During the Mayor’s term, Warren was voted by Money magazine as the sixth best place to live in America; and again by New Jersey Monthly, as the second-best place to live in Central NJ.

Mayor Sordillo will be honored along with Gary DiNardo, Carolann Garafola, and the late Frank Salvato during an event next week.

About Tevogen Bio

Tevogen is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence.

Tevogen is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.

Contacts

Tevogen Bio Communications

T: 1 877 TEVOGEN, Ext 701

 

A photo accompanying this announcement is available at



EN
05/12/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TEVOGEN BIO HOLDINGS INC

 PRESS RELEASE

Repeat - Tevogen.AI Expands Collaboration With Databricks and Microsof...

Repeat - Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology Tevogen.AI to explore external market opportunities as a potential revenue source. Beta version to incorporate oncology targets, enhancing the accuracy and diversity of the PredicTcell model and potentially accelerating cancer immunotherapy development.Tevogen.AI to develop enhanced analytics and visualization tools, for the PredicTcell model to support its internal R&D teams. WARREN, N.J., Aug. 13, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Ho...

 PRESS RELEASE

Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value E...

Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- (“Tevogen” or the “Company) (Nasdaq: ), reiterates investor confidence and estimated asset value over $10 billion. In October 2024, HMP Partners and The Patel Family LLP, investors in innovative healthcare ventures, congratulated Tevogen Bio and Dr. Ryan Saadi for their efforts to alleviate health inequality through breakthrough life-saving medical innovations. Hema Patel, Managing Partner of HMP Partners and The Patel Family LLP, remarked, “We are i...

 PRESS RELEASE

REPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast...

REPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion Treatment of a subgroup of patients with post-acute sequelae of SARS-CoV-2.Forecast adds to Tevogen Bio's Oncology therapeutic area projections of $1 billion in the launch year and $10–$14 billion over the first five years. WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: ), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmod...

 PRESS RELEASE

Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion i...

Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow Total eligible patients in the US exceed 2 million.Treatment of SARS-CoV-2 infection in solid and hematologic cancer patients under active treatment.Reflects business philosophy of commercial success through patient accessibility. WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: ), a clinical-stage specialty immunotherapy biotech dev...

 PRESS RELEASE

REPEAT - Tevogen CEO Affirms Strong Growth, Capital Position, and AI E...

REPEAT - Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today released a letter to stockholders. Dear Fellow Stockholders, Tevogen has rapidly evolved from a biotechnology innovator into a dynamic enterprise expanding into artificial intelligence through Tevogen.AI. Our mission remains steadfast: delivering clinically impactful, economically accessible therapies by leveraging cutting-edge science and technology. ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch